Decrease in viral load associated with topical dinitrochlorobenzene therapy in HIV disease

Research in Virology

Volumn 148, Issue 5, 1997, Pages 343-348

  Stricker, R B ^a   Goldberg, B ^c   Mills, L B ^d   Epstein, W L ^b  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Dinitrochlorobenzene Study Group   (United States)

^d UNIVERSITY OF HAWAII   (United States)

Author keywords

AIDS; DNCB; HIV; Therapy; Viral load

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MEASUREMENT; NONHUMAN; PLASMA; PRIORITY JOURNAL; QUANTITATIVE ASSAY; TOPICAL DRUG ADMINISTRATION; UNITED STATES;

ANURA; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030722954     PISSN: 09232516     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0923-2516(97)89130-3     Document Type: Article

References (21)

1. Borman, A.M., Paulous, S. & Clavel, F. (1996), Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J. Gen. VIrol., 77, 419-426.
2. + T lymphocyte subsets to the cytokine secretion patterns induced in mice during sensitization to contact and respiratory chemical allergens. Immunology, 89, 502-510.
3. Katzenstein, D.A., Holodniy, M., Israelski, D.M., Sengupta, S., Mole, L.A., Bubp, J.L. & Merigan, T.C. (1992), Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment. JAIDS, 5, 107-112.
4. Katzenstein, T.L., Pedersen, C., Nielsen, C., Lundgren, J.D., Jakobsen, P.H. & Gerstoft, J. (1996), Longitudinal serum HIV RNA quantification: correlation to a viral phenotype at seroconversion and clinical outcome. AIDS, 10, 167-173.
5. Lafeuillade, A., Tamalet, C., Poggi, C., Pellegrino, P., Tourres, C. & Izopet, J. (1997), Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes. AIDS, 11, 67-72.
6. Matsiota-Bernard, P., Guétard, D., Rame, V., Montagnier, L. & Avrameas, S. (1995), Inhibition of in vitro HIV infection by trinitrophenyl-protein conjugates. Res. Virol., 146, 109-117.
7. Medina, D.J., Tung, P.P., Lerner-Tung, M.B., Nelson, C.J., Mellors, J.W. & Strair, R.K. (1995), Sanctuary growth of human immunodeficiency virus in the presence of 3′-azido-3′-deoxythymidine. J. Virol., 69, 1606-1611.
8. Mellors, J.W., Kingsley, L.A., Rinaldo, C.R., Todd, J.A., Hoo, B.S., Kokka, R.P. & Gupta, P. (1995), Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med., 122, 573-579.
9. Mulder, J., McKinney, N., Christopherson, C., Sninsky, J., Greenfield, L. & Kwok, S. (1994), Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J. Clin. Microbiol., 32, 292-300.
10. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M. & Ho, D.D. (1996), HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science, 271, 1582-1586.
11. Saag, M.S., Holodniy, M., Kuritzkes, D.R., O'Brien, W.A., Coombs, R.W., Poscher, M.E., Jacobsen, D.M., Shaw, G.M., Richman, D.D. & Volberding, P.A. (1996), HIV viral load markers in clinical practice. Nat. Med., 2, 625-629.
12. Stricker, R.B., Zhu, Y.S., Elswood, B.F., Dumlao, C., Van Elk, J., Berger, T.G., Tappero, J., Epstein, W.L. & Kiprov, D.D. (1993), Pilot study of topical dinitrochlorobenzene (DNCB) in human immunodeficiency virus infection. Immunol. Letters, 36, 1-6.
13. Stricker, R.B., Elswood, B.F., Goldberg, B., Dumlao, C., Van Elk, J., Henry, J., Winger, E.E. & Espstein, W.L. (1994), Clinical and immunologic evaluation of HIV-infected patients treated with dinitrochlorobenzene (DNCB). J. Am. Acad. Dermatol., 31, 462-466.
14. Stricker, R.B., Goldberg, B., Mills, L.B. & Epstein, W.L. (1995a), Improved results of delayed-type hypersensitivity skin testing in HIV-infected patients treated with topical dinitrochlorobenzene. J. Am. Acad. Dermatol., 33, 608-611.
15. Stricker, R.B., Zhu, Y.S. & Elswood, B.F. (1995b), Quantitation of human immunodeficiency virus type 1 (HIV-1) RNA in plasma: clinical correlates. Res. Virol., 146, 151-158.
16. Stricker, R.B. & Goldberg, B. (1996), Increase in lymphocyte subsets following treatment of HIV-associated neutropenia with granulocyte colony-stimulating factor. Clin. Immunol. Immunopathol., 79, 194-196.
17. Stricker, R.B., Goldberg, B. & Epstein, W.L. (1997), Combination antiretroviral therapy and topical immune modulation with dinitrochlorobenzene (DNCB) in HIV disease. J. Allergy Clin. Immunol., 99, S-48.
18. Terashita, M., Kudo, C., Yamashita, T., Gresser, I. & Sendo, F. (1996), Enhancement of delayed-type hypersensitivity to sheep red blood cells in mice by granulocyte colony-stimulating factor administration at the elicitation phase. J. Immunol., 156, 4638-4643.
19. Traub, A. & Margulis, S.B. (1995), Use of dinitrochlorobenzene (DNCB) as an immune modulator in HIV-positive patients: a pilot study from Brazil. Blood, 86(Suppl.), 935a.
20. Volberding, P.A. (1996), HIV quantification: clinical applications. Lancet, 347, 71-73.
21. Zhu, Y.S., Gong, Y. & Cimino, G.D. (1995), Quantitative analysis of HIV-1 RNA in plasma preparations. J. Virol. Methods, 52, 287-299.